Janssen wins DVT, PE indications in US for Xarelto
This article was originally published in Scrip
Executive Summary
Johnson & Johnson unit Janssen won the US FDA's blessing to market the firm's blood-thinning agent Xarelto (rivaroxaban) to treat deep vein thrombosis (DVT) or pulmonary embolism (PE), and as a threapy to reduce the risk of recurrent DVT and PE following initial treatment.